Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 5Recruiting 2Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 117Squamous Cell Carcinoma of Head and Neck 61Triple Negative Breast Neoplasms 55Melanoma 54Lung Neoplasms 49Neoplasm Metastasis 47Breast Neoplasms 42Neoplasms 38Colorectal Neoplasms 37Head and Neck Neoplasms 26Endometrial Neoplasms 25Carcinoma, Renal Cell 25Ovarian Neoplasms 22Uterine Cervical Neoplasms 21Stomach Neoplasms 21Carcinoma, Transitional Cell 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 19Recurrence 16Esophageal Neoplasms 16Pancreatic Neoplasms 15Carcinoma, Hepatocellular 14Sarcoma 12Glioblastoma 12Carcinoma, Squamous Cell 12Prostatic Neoplasms 11Esophageal Squamous Cell Carcinoma 11Carcinoma 11Brain Neoplasms 10Carcinoma, Merkel Cell 9

Interventions

Gemcitabine 7Oxaliplatin 6Cisplatin 5durvalumab 3130-nm albumin-bound paclitaxel 3pembrolizumab 2Leucovorin 2Drug Therapy 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1sintilimab 1pertuzumab 1anlotinib 1Trastuzumab 1Taxes 1Standard of Care 1Platinum 1Observation 1Nivolumab 1Neoadjuvant Therapy 1Long-Term Synaptic Depression 1Irinotecan 1Folfox protocol 1Fluorouracil 1Everolimus 1Commerce 1Cholangiopancreatography, Endoscopic Retrograde 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Gallbladder Neoplasms × pembrolizumab × Clear all
NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PMV Pharmaceuticals, Inc

Phase 1/2 Recruiting
300 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡